Zymeworks
Manufacturing · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 E 4th Ave Ste 800, Vancouver, Britis...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$81.3 MillionStock Symbol
ZYMEIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
1
1
1
1
About Zymeworks
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.Explore more
Zymeworks Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Zymeworks had a recent Job posting/layoffs
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Zymeworks launches new products
Check out if Zymeworks is spiking on competitors!
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Zymeworks has new funding data
Recommended Actions
Find VP level buyers at Zymeworks
Find 2 more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zymeworks is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$22.3M
2015
Multiple Rounds
$34.4M
2016
Series A
$61.5M
2017
Stock Offering
$63.6M
2018
Stock Offering
$97.8M
2019
Stock Offering
$201.3M
2020
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
See more technologies
Most Recent Scoops
Open Position
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Research & Development
Person-Based
Pharmaceuticals
Zymeworks News & Media
Zymeworks agrees to buy Theravance Biopharma for $929m
The boards of both companies unanimously approved the agreement, which remains subject to shareholder and regulatory approvals.Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call June 29, 2026 8:30 AM EDTCompany ParticipantsShrinal Inamdar - VP of Investor RelationsKenneth Galbraith - Chairman of...Zymeworks to Acquire Theravance Biopharma, Inc.
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference® in people’s lives. This proposed acquisitTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Sign Up For FreeTo access detailed company insights
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.... Read More
